Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ibrutinib, Obinutuzumab Are Early Tests Of How Fast Breakthrough Reviews Will Be

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Ibrutinib application is among the first for a breakthrough therapy designee and should provide an early indicator of FDA review expectations for the newest expedited approval program.

You may also be interested in...



A “Breakthrough” Reality Check: Sponsors Seek FDA Flexibility On Manufacturing, Diagnostics

FDA’s much-anticipated guidance on expedited programs for drug development fills in some blanks on the new breakthrough designation, but simply advising sponsors they will need to pick up the pace on manufacturing plans and development of companion diagnostics leaves aspiring applicants wanting more, stakeholders said at DIA.

What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers

Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.

Breakthrough Therapies: FDA Not Writing A Scientific Guidance – Yet

The agency needs more experience making the decisions before it lays out the evidence threshold for a breakthrough designation, CDER Director Janet Woodcock says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel